Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bedoradrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.70 |
| ▸ | ADRB3 | P13945 | 14/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bedoradrine SCHEMBL29385851 | 1.00 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694819 | 1.00 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL678131 | 1.00 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3694818 | 1.00 | ADRB1 (0.70) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL7586092 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828783 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL29379919 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL3828780 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Bedoradrine SCHEMBL10026405 | 0.98 | ADRB1 (0.73) | ADRB1ADRB2ADRB3 | |
| Sulfuric Acid SCHEMBL5449137 | 0.93 | ADRB1 (0.60) | ADRB1ADRB2ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251632-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. | 2012-10-04 | — | — | US | disclosed |
| EP-2501228-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MediciNova, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7985756-B2 | Modulation of neurogenesis by PDE inhibition | BRAINCELLS INC. (US) | 2011-07-26 | — | — | US | disclosed |
| WO-2011063115-A1 | COMBINATION OF NOOTROPIC AGENT WITH ONE OR MORE NEUROGENIC OR NEUROGENIC SENSITIZING AGENTS FOR STIMULATING OR INCREASING NEUROGENESIS | BRAINCELLS INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011062984-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20110117213-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | MEDICINOVA, INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2007134077-A2 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060052458-A1 | Preventive or remedy for intrauterine late embryonic development or pregnancy toxemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1591115-A1 | PREVENTIVE OR REMEDY FOR INTRAUTERINE LATE EMBRYONIC DEVELOPMENT OR PREGNANCY TOXEMIA | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | ADRB2 410/4885ADRB1 576/4885ADRB3 447/4885 |
| US-20120251632-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | CHRM3, CHRM2, CHRM5 | ADRB2 21/4885ADRB1 31/4885ADRB3 12/4885 |
| US-20070208029-A1 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | PDE2A, PDE4A, DCX | ADRB2 1012/4885ADRB1 1082/4885ADRB3 782/4885 |
| US-20110117213-A1 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM | CHRM3, CHRM2, CHRM5 | ADRB2 21/4885ADRB1 31/4885ADRB3 12/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | ADRB2 745/4885ADRB1 730/4885ADRB3 568/4885 |
| US-20060052458-A1 | Preventive or remedy for intrauterine late embryonic development or pregnancy toxemia | TST, PGF, FABP6 | ADRB2 1242/4885ADRB1 650/4885ADRB3 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.